Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments

Reuters

Aug 29

Altamira <a href="https://laohu8.com/S/LENZ">Therapeutics</a> Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments

Altamira Therapeutics Ltd. has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altamira Therapeutics Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1066695) on August 29, 2025, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

1
2
3
4
5
6
7
8
9
10

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2563014047"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2563014047\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2563014047?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-08-29 19:42","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2563014047","market":"fut","top_or_hot":-1,"title":"Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altamira <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CYTO\">Altamira Therapeutics Ltd.</a> has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CYTOF\">Altamira Therapeutics Ltd.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1066695) on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nAltamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-08-29 19:42</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Altamira <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/CYTO\">Altamira Therapeutics Ltd.</a> has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. <a href=\"https://laohu8.com/S/CYTOF\">Altamira Therapeutics Ltd.</a> published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1066695) on August 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CYTOF","symbol_name":"Altamira Therapeutics Ltd.","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250829:nNDL6NvttB:1","article_id":"2563014047","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2563014047","pubTimestamp":1756467776,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments. Altamira Therapeutics Ltd. has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not b","collect":0,"end_time":0,"defaultTopTitle":"","property":["rate"],"viewcount":null,"language":"en","relate_stocks":{"CYTOF":"Altamira Therapeutics Ltd."},"translate_title":"Altamira Therapeutics预计部分分拆ATAG后运营费用将减少，并计划根据新进展更新财务指引","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CYTOF":0.9},"content_text":"Altamira Therapeutics Anticipates Reduced Operating Expenses Following Partial Spin-off of ATAG, Plans to Update Financial Guidance with New Developments\n    \n\nAltamira Therapeutics Ltd. has announced that it expects its operating expenses to decrease significantly upon the completion of the planned partial spin-off of its ATAG subsidiary. The company plans to support its operations through its current cash position, proceeds from the sale of ATAG shares to private equity investors, as well as through partnering or divesting legacy assets and providing services for associates. Altamira has stated that it will update its financial guidance as new, material information becomes available, particularly regarding the anticipated partial spin-off of ATAG.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Altamira Therapeutics Ltd. published the original content used to generate this news brief via ACCESS Newswire (Ref. ID: 1066695) on August 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"event","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}